Reducing uncertainty in health-care resource allocation

British Journal of Cancer

Volumn 96, Issue 12, 2007, Pages 1834-1838

  Simonsson, T ^a   Sjolund K ^a   Bumming P ^a   Ahlman, H ^a   Nilsson, B ^a   Oden A ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Gastrointestinal stromal tumour; GIST; Imatinib mesylate; Quality of life; Survival; Treatment

Indexed keywords

IMATINIB;

ACCURACY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG COST; DRUG INDUSTRY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAZARD ASSESSMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROFIT; QUALITY OF LIFE;

DELIVERY OF HEALTH CARE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROPORTIONAL HAZARDS MODELS; QUALITY-ADJUSTED LIFE YEARS; RESOURCE ALLOCATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SWEDEN;

EID: 34250346792     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603795     Document Type: Article

References (18)

1. Berenson A (2005) Cancer drugs offer hope, but at huge expense. NY Times (Print), A1, C3
2. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488
3. Breslow NE, Day NE (1987) Statistical Methods in Cancer Research. Volume II-The Design and Analysis of Cohort Studies. IARC Scientific Publication No. 82. Lyon: International Agency for Research on Cancer, pp 131-135
4. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100-104
5. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M (2005) Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366: 1784-1793
6. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW (1997) Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford: Oxford University Press
7. Goldman J (2005) Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients? Nat Clin Pract Oncol 2: 126-127
8. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science 279: 577-580
9. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumour. N Engl J Med 344: 1052-1056
10. Kind P (1996) The EuroQoL instrument: an index of health-related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn (Spilker B ed). Philadelphia: Lippincott-Raven, pp 191-201
11. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, Uberbacher E, Frazier M, Gibbs RA, Muzny DM, Scherer SE, Bouck JB, Sodergren EJ, Worley KC, Rives CM, Gorrell JH, Metzker ML, Naylor SL, Kucherlapati RS, Nelson DL, Weinstock GM, Sakaki Y, Fujiyama A, Hattori M, Yada T, Toyoda A, Itoh T, Kawagoe C, Watanabe H, Totoki Y, Taylor T, Weissenbach J, Heilig R, Saurin W, Artiguenave F, Brottier P, Bruls T, Pelletier E, Robert C, Wincker P, Smith DR, Doucette-Stamm L, Rubenfield M, Weinstock K, Lee HM, Dubois J, Rosenthal A, Platzer M, Nyakatura G, Taudien S, Rump A, Yang H, Yu J, Wang J, Huang G, Gu J, Hood L, Rowen L, Madan A, Qin S, Davis RW, Federspiel NA, Abola AP, Proctor MJ, Myers RM, Schmutz J, Dickson M, Grimwood J, Cox DR, Olson MV, Kaul R, Raymond C, Shimizu N, Kawasaki K, Minoshima S, Evans GA, Athanasiou M, Schultz R, Roe BA, Chen F, Pan H, Ramser J, Lehrach H, Reinhardt R, McCombie WR, de la Bastide M, Dedhia N, Blocker H, Hornischer K, Nordsiek G, Agarwala R, Aravind L, Bailey JA, Bateman A, Batzoglou S, Birney E, Bork P, Brown DG, Burge CB, Cerutti L, Chen HC, Church D, Clamp M, Copley RR, Doerks T, Eddy SR, Eichler EE, Furey TS, Galagan J, Gilbert JG, Harmon C, Hayashizaki Y, Haussler D, Hermjakob H, Hokamp K, Jang W, Johnson LS, Jones TA, Kasif S, Kaspryzk A, Kennedy S, Kent WJ, , Kitts P, Koonin EV, Korf I, Kulp D, Lancet D, Lowe TM, McLysaght A, Mikkelsen T, Moran JV, Mulder N, Pollara VJ, Ponting CP, Schuler G, Schultz J, Slater G, Smit AF, Stupka E, Szustakowski J, Thierry-Mieg D, Thierry-Mieg J, Wagner L, Wallis J, Wheeler R, Williams A, Wolf YI, Wolfe KH, Yang SP, Yeh RF, Collins F, Guyer MS, Peterson J, Felsenfeld A, Wetterstrand KA, Patrinos A, Morgan MJ, de Jong P, Catanese JJ, Osoegawa K, Shizuya H, Choi S, Chen YJ (2001) Initial sequencing and analysis of the human genome. Nature 409: 860-921
12. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312: 1254-1259
13. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG (2005) Gastrointestinal stromal tumours: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 103: 821-829
14. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (2005) SEER Cancer Statistics Review, 1975 - 2002. Bethesda, MD: National Cancer Institute
15. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938-1942
16. Smith M (2005) Oh, Canada: public outcry pushed demand for trastuzumab for early-stage breast cancer. J Natl Cancer Inst 97: 1327
17. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD (2001) STI571 inactivation of the gastrointestinal stromal tumour c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-5058
18. Wilking N, Jonsson B (2005) A Pan-European Comparison Regarding Patient Access to Cancer Drugs. Stockholm: Karolinska Institute in collaboration with Stockholm School of Economics